Boston Therapeutics Inc. (BTHE)
Stock Price: $0.0247 USD
0.0047 (23.50%)
Updated Jun 11, 2021 12:09 PM EDT - Market closed
| Market Cap | 22.65M |
| Revenue (ttm) | 9,336 |
| Net Income (ttm) | -907,883 |
| Shares Out | 916.92M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $0.0247 |
| Previous Close | $0.0200 |
| Change ($) | 0.0047 |
| Change (%) | 23.50% |
| Day's Open | 0.0247 |
| Day's Range | 0.0247 - 0.0247 |
| Day's Volume | 524 |
| 52-Week Range | 0.0055 - 0.0600 |
News
There are no news available yet.
About BTHE
Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical development company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. The company's lead pharmaceutical drug candidates are BTI-320, a non-systemic carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phas... [Read more...]
| Industry Biotechnology | Founded 2009 |
| Stock Exchange OTCMKTS | Ticker Symbol BTHE |
Financial Performance
In 2020, BTHE's revenue was $9,336, a decrease of -42.83% compared to the previous year's $16,329. Losses were -$907,883, -75.42% less than in 2019.